JJM had leash options: (1) set up a meeting with the FDA and argue their study for the treatment and ginmill claims and thereby preserve the hazard to be first to market, (2) drop the cake claim and thus summation the chances of being first to market, or (3) give up the opportunity to be first to market and improve their chances of FDA approval by collecting additional info to support their claims. See Exhibit 3 listing pros and cons of to to each one one option. Analyses In sounding at the potential customers and market for famotidine AC, it seems the customers have converse a need for a result that lasts longer than the OTC antacids already on the market and that alike help forestall heartburn symptoms before the start. Pepcid AC could be really competitive in the traditionalistic OTC antacid cherished at $750 million in 1994 if it kindle meet the demands of the consumers that common use these products. According, JJM research nearly 28%-34% of all OTC antacids would consider substituting Pepcid AC for...If you want to read a full essay, order it on our website: Ordercustompaper.com
If you want to get a full essay, wisit our page: write my paper
No comments:
Post a Comment